At AR Therapeutics, our mission is to advance the development of targeted therapies for age-related disorders through breakthrough science, innovation, and precision drug discovery. Aging and Alzheimer’s disease represent one of the largest unmet medical needs worldwide, with the Alzheimer’s therapeutics market alone projected to exceed $20 billion by 2030. Despite recent approvals, most available therapies offer modest symptomatic relief rather than disease modification. AR Therapeutics is uniquely positioned to capture significant market share by focusing on novel first-in-class small molecules that directly address the biological and genetic drivers of neurodegeneration.

We are pioneering GFAP-targeted small molecules that disrupt neuroinflammatory pathways and halt aggregate progression—an area currently underserved by existing Alzheimer’s pipelines. In parallel, our ApoE4-directed small molecules are designed to reduce the elevated risk associated with inheriting the APOE4 genotype, which increases Alzheimer’s susceptibility up to 15-fold. While many competitors concentrate on amyloid and tau clearance, AR Therapeutics differentiates itself by addressing both glial biology and genetic risk factors, creating a dual-pronged strategy with high clinical and commercial potential. This positions us ahead of the curve, tapping into segments of the market that remain largely unaddressed by traditional players.

For investors, AR Therapeutics offers a compelling opportunity at the intersection of science, innovation, and global health need. By combining a novel mechanistic focus with strong intellectual property protection, scalable discovery platforms, and early proof-of-concept successes, we are building a pipeline with the potential for category-leading therapies. Our unique positioning not only diversifies risk compared to single-target competitors but also opens multiple revenue streams across the Alzheimer’s and neurodegenerative disease market landscape. With innovation driving our science and a strategic vision guiding our growth, AR Therapeutics is poised to deliver transformative therapies while unlocking multi-billion-dollar market potential.